NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
NewAmsterdam Pharma Company N.V. (NAMS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $20.43 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2026-03-31 was $20.56, a 55.29% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-03-31 was $13.24, a 124.41% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $5.90, a 22.41% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $4.82.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $12.66, a 88.96% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $6.70, a 42.55% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $4.70, a 8.80% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $4.32, a 289.19% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.43 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $20.56 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $12.66 10-K · filed 2026-02-18 | |||
| 2025-09-30 | $12.54 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $12.68 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $13.24 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $6.70 10-K · filed 2026-02-18 | |||
| 2024-09-30 | $6.60 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $6.30 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $5.90 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $4.70 10-K · filed 2026-02-18 | |||
| 2023-09-30 | $4.83 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $4.86 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $4.82 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $4.32 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $1.11 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |